
Sonnet BioTherapeutics’ Global IP Collection Grows: A New EU Patent for FHAB Technology
Europe’s Latest Biotech Breakthrough: Fully Human Albumin Binding (FHAB®) Domain Fusion Proteins In a recent development that’s sending ripples through the biotech industry, the European Patent Office (EPO) has granted EU Patent No. EP3583125 B1 to a leading biotech company for their innovative Fully Human Albumin Binding (FHAB®) domain fusion proteins. This patent protects the…